BLUE News and Press, bluebird bio Inc. From 06/13/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bluebird Bio ( BLUE ) stock is rising alongside FDA news today. This includes two recommendations for its therapies from an advisory committee. That has shares of BLUE seeing heavy trading today. Source: Buk...

Following two days of trading halts, commercial-stage biotech bluebird bio, Inc. (NASDAQ:BLUE) climbed 71% in the pre-market Monday after an expert panel of the FDA endorsed two lentiviral vector (LVV)-based gene therapies developed by the company. On Thursday, FDA’s Cellular...

Are These The Best Biotech Stocks To Buy Right Now? Even with inflation data coming in hotter-than-expected, investors would likely be looking for the most active stocks today. Should this be the case, biotech stocks would make for a viable option in the stock market now. For th...

An independent panel of experts of the FDA unanimously recommended a gene therapy developed by Bluebird bio (NASDAQ:BLUE) for regulatory authorization as a treatment for β-thalassemia on Friday. FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted 13-0 in favor of...

Current standard of care relies on regular red blood cell transfusions and iron management that carry the risk of progressive multi-organ damage and increased risk of morbidity and mortality If approved, beti-cel will be the first potentially curative gene therapy option for ...

An aging population and unmet clinical needs are driving biotech companies toward advancements in medicine to keep people healthier longer. Bluebird Bio (NASDAQ: BLUE) is one of those companies, and it's hoping that an existing U.S. Food and Drug Administration (FDA) panel review wi...

Bluebird bio (NASDAQ:BLUE) is set to win the backing of a key FDA committee for a gene therapy candidate for β-thalassemia after the biotech received its strong support for a similar drug targeting a rare neurodegenerative on Thursday, Morgan Stanley argues. The company shares remain o...

Bluebird bio (NASDAQ:BLUE) said a panel of the U.S. Food and Drug Administration (FDA) voted in favor of its gene therapy candidate elivaldogene autotemcel (eli-cel) for cerebral adrenoleukodystrophy (CALD). The company's stock had been halted for trading by Nasdaq on June 9 for 2 days (...

If approved, eli-cel will be the first and only gene therapy for the treatment of early active CALD, a rare neurodegenerative disease that primarily affects young children and leads to irreversible loss of neurologic function and death PDUFA goal date is set for September 16, ...

Bluebird bio (NASDAQ:BLUE) said Nasdaq has halted trading of its common shares for June 9-10, ahead of a U.S. Food and Drug Administration (FDA) panel meeting to discuss applications seeking approval of its gene therapies. Earlier in the week, the company's shares gained after the FDA re...